* HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. ...
* HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of430...
* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KR...
ROCKVILLE, Md. and SEOUL, South Korea, July 15, 2024 /PRNewswire/ -- HanAll Biopharma (KRX: 009420....
* Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technolo...
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanerc...
* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 bi...
* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D mome...
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceu...
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc....
* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, ...
* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development o...
* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sus...
* HanAll Biopharma and Daewoong Pharmaceutical have co-invested in Vincere Biosciences. * These...
* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel inve...
* Tanfanercept did not demonstrate statistical significance in either of the primary outcome meas...
* Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percen...
* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical bus...
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The...
* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile...